Efficiency and safety of convalescent plasma therapy in patients with COVID-19: a systematic review

Ладыгина, Е. А.; Kostin, Alexander I.; Bulanov, A. Yu.

doi:10.21320/1818-474x-2022-2-108-120

Cited by 5 publications

(6 citation statements)

References 62 publications

(64 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…35 The success of CPT is also influenced by factors such as disease severity, comorbidities, complications and length of stay. 29,[35][36][37] There was no association between changes in s-RBD IgG, IL-4 and IL-6 levels after administration of CPT and mortality. IL-6 is an adequate predictor of disease severity but is not correlated with mortality.…”

Section: Dovepressmentioning

confidence: 87%

“…Administration of CPT may be effective in eliminating the virus but not sufficient to reduce lung damage due to inflammation in patients with advanced or critical stages of COVID-19. 37 This study has several limitations, including the limited number of subjects conducted at the start of the COVID-19 pandemic, so the choice of therapy and examination was still limited. Monitoring of biomarkers was only carried out until the 7th day after CPT without following until the end of clinical outcome monitoring, the time from the onset of the first symptoms to hospital admission and obtaining CPT was different for each patient and was not a criterion for analysis so that the patient was not known in the immunopathological phase when CPT was administered.…”

Section: Dovepressmentioning

confidence: 99%

See 1 more Smart Citation

Immunomodulation Effect of Convalescent Plasma Therapy in Severe – Critical COVID-19 Patients

Fitriah¹,

Putri²,

Semedi³

et al. 2023

OAEM

View full text Add to dashboard Cite

Introduction: Convalescent plasma therapy (CPT) is an alternative therapy for managing COVID-19, but its use is still controversial. Objective: Analyzing the effectiveness of CPT in modulating immune responses based on SARS-COV-2 anti-spike protein receptorbinding domain (s-RBD) IgG, inflammatory cytokines (IL-6 and IL-4), and mortality in severe-critical COVID-19 patients. Methods: This study was an observational analytical with a prospective cohort design. The number of participants was 39 patients from June to December 2020. The participants received CPT and was tested for blood analysis such as IL-4, IL-6 and s-RBD IgG. The data were taken a day before CPT, 1st day, 2nd day, and 7th day after CPT. The analysis included Friedman, Pearson correlation, and Mann-Whitney test which is significant if p <0.05. Results:The value of participant's s-RBD IgG before CPT was 91.49 (0.43-3074.73) AU/mL and the 7th day post-CPT, s-RBD IgG value of 1169.79 (6.48-5577.91) AU/mL (p <0.001). The IL-4 value before CPT was 1.78 (0.85-5.21) ng/mL and the 7th day post-CPT, IL-4 value of 1.97 (0.87-120.30) ng/mL (p = 0.401). The condition was also found in IL-6 value, in which the IL-4 value participant before CPT was 109.61 (0.73-4701.63) ng/mL and the 7th day post-CPT, IL-6 value of 1.97 (0.87-120.30) ng/mL (p = 0.401). No significant correlation found between increased s-RBD IgG level with increased IL-4 and decreased IL-6 before and after CPT in severe-critical COVID-19 patients (p >0.05). No significant correlation was also found between increased s-RBD IgG levels, IL-4 too, and decreased IL-6 after CPT therapy between deceased and alive patients, both in 1st, 2nd, and 7th days (p >0.05). Conclusion:No correlation between the increase in s-RBD IgG levels and changes in IL-4 and IL-6 levels. Changes in s-RBD IgG, IL-4, and IL-6 levels are not associated with mortality in severe-critical COVID-19 degree post CPT recipients.

show abstract

Section: Dovepressmentioning

confidence: 87%

Section: Dovepressmentioning

confidence: 99%

Immunomodulation Effect of Convalescent Plasma Therapy in Severe – Critical COVID-19 Patients

Fitriah¹,

Putri²,

Semedi³

et al. 2023

OAEM

View full text Add to dashboard Cite

show abstract

“… According to the study’s findings, CP boosted IgG and IgM levels in the ICU, preventing COVID-19-related deaths. Alessandra Oliva et al 166 CP for hematological patients with significant B-CD lymphocytes and SARS-CoV-2 pneumonia after anti-CD20 therapy (ORA) RS observational study October 2020 to May 2021 Six COVID-19 patients with non-HL and a lack of B-cells were studied. CP was administered in the context of pneumonia with respiratory failure despite normal Tx and comprised 3 infusions on alternate days - Remdesivir, corticosteroids, and LMWH.…”

Section: Introductionmentioning

confidence: 99%

“… E.A. Ostrovskaya 166 CPT efficiency and safety in COVID-19 patients: An SR June 7, 2021, to December 20, 2021 PubMed, MedRxiv, Cochrane Library −29 full-text articles RS and prospective studies related to CP therapy The criteria for effectiveness and timing for transfusion of the CP were considered. In seronegative patients with COVID-19 during an early stage of the illness or the existence of the IDs state, CP administration is safe and appropriate.…”

Section: Introductionmentioning

confidence: 99%

Effectiveness of COVID-19 Convalescent Plasma (CCP) During the Pandemic Era: A Literature Review

Kandula¹,

Tuji²,

Gudeta³

et al. 2023

JBM

View full text Add to dashboard Cite

Worldwide pandemic with coronavirus disease-2019 (COVID-19) was caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). As November 2, 2022, World Health Organization (WHO) received 628,035,553 reported incidents on COVID-19, with 6,572,800 mortalities and, with a total 12,850,970,971 vaccine doses have been delivered as of October 31, 2022. The infection can cause mild or self-limiting symptoms of pulmonary and severe infections or death may be caused by SARS-CoV-2 infection. Simultaneously, antivirals, corticosteroids, immunological treatments, antibiotics, and anticoagulants have been proposed as potential medicines to cure COVID-19 affected patients. Among these initial treatments, COVID-19 convalescent plasma (CCP), which was retrieved from COVID-19 recovered patients to be used as passive immune therapy, in which antibodies from cured patients were given to infected patients to prevent illness. Such treatment has yielded the best results in earlier with preventative or early stages of illness. Convalescent plasma (CP) is the first treatment available when infectious disease initially appears, although few randomized controlled trials (RCTs) were conducted to evaluate its effectiveness. The historical record suggests with potential benefit for other respiratory infections, as coronaviruses like Severe Acute Respiratory Syndrome-CoV-I (SARS-CoV-I) and Middle Eastern Respiratory Syndrome (MERS), though the analysis of such research is constrained by some non-randomized experiments (NREs). Rigorous studies on CP are made more demanding by the following with the immediacy of the epidemics, CP use may restrict the ability to utilize it for clinical testing, non-homogenous nature of product, highly decentralized manufacturing process; constraints with capacity to measure biologic function, ultimate availability of substitute therapies, as antivirals, purified immune globulins, or monoclonal antibodies. Though, it is still not clear how effectively CCP works among hospitalized COVID-19 patients. The current review tries to focus on its efficiency and usage in clinical scenarios and identifying existing benefits of implementation during pandemic or how it may assist with future pandemic preventions.

show abstract

“…Использование ССР на ранних этапах заболевания оказалось эффективным средством лечения, хотя ее клиническая эффективность не всегда была доказана [2][3][4][5][6]. Тяжесть состояния, ранние сроки применения и наличие иммуносупрессии оказывали существенное влияние на результаты лечения COVID-19 с использованием ССР [1,[4][5][6][7]. При этом отмечено, что терапевтическое действие ССР связано не только с наличием противовирусных антител, но также Оригинальные исследования.…”

unclassified

Clinical and Laboratory Characteristics of COVID-19 Patients with Different Outcome, Treated with Convalescent Plasma

Дунаев,

Потапнёв,

Максимович

et al. 2024

Гематология. Трансфузиология. Восточная Европа

View full text Add to dashboard Cite

Проведен анализ клинических, функциональных и лабораторных показателей пациентов с COVID-19, получавших терапию плазмой иммунной анти-COVID-19 (CCP). Сравнение пациентов группы выздоровевших (n=84) и умерших (n=27) показало, что факторами риска смертельного исхода при проведении терапии являются: возраст более 65 лет, уровень потока кислорода через носовые канюли более 10 л/мин (p=0,00027), потребность в ИВЛ (p=0,02), повышенные уровни лейкоцитов и нейтрофилов периферической крови до трансфузии ССР (p=0,0055 и p=0,0063 соответственно), возрастание уровня нейтрофилов периферической крови (p=0,00027) и уровня СОЭ и С-реактивного белка после трансфузии ССР (p=0,0045 и p=0,0001 соответственно). Сделан вывод о различии прогностически значимых клинико-лабораторных показателей у пациентов, выздоровевших или впоследствии умерших, при применении терапии с использованием ССР. The analysis of clinical, functional and laboratory parameters of patients with COVID-19 who received therapy with immune anti-COVID-19 plasma (CCP) was carried out. The comparison of groups the recovered (n=84) and deceased (n=27) patients showed that the risk factors for death were: age of patients over 65 years, the level of oxygen flow through nasal cannulas over 10 l/min (p=0.00027), need for mechanical ventilation (p=0.02), increased levels of leukocytes and neutrophils of peripheral blood before CCP transfusion (p=0.0055 and p=0.0063, respectively), increased levels of peripheral blood neutrophils (p=0.00027) and levels of ESR and C-reactive protein after CCP transfusion (p=0.0045 and p=0.0001, respectively). The conclusion was made for existence of discrepancy between prognostically significant clinical and laboratory parameters of patients with recovered or deceased outcome when used CCP in COVID-19 therapy.

show abstract

Efficiency and safety of convalescent plasma therapy in patients with COVID-19: a systematic review

Cited by 5 publications

References 62 publications

Immunomodulation Effect of Convalescent Plasma Therapy in Severe – Critical COVID-19 Patients

Immunomodulation Effect of Convalescent Plasma Therapy in Severe – Critical COVID-19 Patients

Effectiveness of COVID-19 Convalescent Plasma (CCP) During the Pandemic Era: A Literature Review

Clinical and Laboratory Characteristics of COVID-19 Patients with Different Outcome, Treated with Convalescent Plasma

Contact Info

Product

Resources

About